Drupal.behaviors.print = function(context) {window.print();window.close();}>
Cancer Genetics Testing Firm NeoGenomics Eyes $7.8M from Public Offering of Stock
February 28, 2013
Cancer Genetics Testing Firm NeoGenomics Eyes $7.8M from Public Offering of Stock
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Cancer Test Firm NeoGenomics Reports Q1 Revenues up 3 Percent
April 25, 2013 / GenomeWeb Daily News
Neogenomics Revenues Grow 49 Percent, Sees Profit in Q2
July 20, 2012 / GenomeWeb Daily News
Health Discovery, NeoGenomics Sign Cancer Testing License Pact
January 9, 2012 / GenomeWeb Daily News
Cenix, Debiopharm Ink Biomarker ID Deal
May 23, 2013 / GenomeWeb Daily News
Industry Observers Question Myriad's Competitive Advantage as It Looks to Launch NGS Cancer Panel
May 22, 2013 / Clinical Sequencing News